Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2003;93:1120-1126
Published online before print October 30, 2003, doi: 10.1161/01.RES.0000103634.69868.4F
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
93/11/1120    most recent
01.RES.0000103634.69868.4Fv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dewerchin, M.
Right arrow Articles by Herbert, J.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dewerchin, M.
Right arrow Articles by Herbert, J.-M.
Related Collections
Right arrow Animal models of human disease
Right arrow Genetically altered mice
Right arrow Coagulation
Right arrow Heparin
Right arrow Thrombosis risk factors
(Circulation Research. 2003;93:1120.)
© 2003 American Heart Association, Inc.


Integrative Physiology

Life-Threatening Thrombosis in Mice With Targeted Arg48-to-Cys Mutation of the Heparin-Binding Domain of Antithrombin

Mieke Dewerchin, Jean-Pascal Hérault, Goedele Wallays, Maurice Petitou, Paul Schaeffer, Laurence Millet, Jeffrey I. Weitz, Lieve Moons, Désiré Collen, Peter Carmeliet, Jean-Marc Herbert

From the Center for Transgene Technology and Gene Therapy (M.D., G.W., L. Moons, D.C., P.C.), VIB, KULeuven Campus Gasthuisberg O&N, Leuven, Belgium; Cardiovascular/Thrombosis Research Department (J.-P.H., M.P., P.S., L. Millet, J.-M.H.), Sanofi-Synthélabo, Toulouse Cedex, France; Hamilton Civic Hospitals Research Centre (J.I.W.), Hamilton, Ontario, Canada.

Correspondence to Mieke Dewerchin, PhD, Center for Transgene Technology and Gene Therapy, VIB, KULeuven Campus Gasthuisberg O&N, Herestraat 49, B-3000 Leuven, Belgium. E-mail mieke.dewerchin{at}med.kuleuven.ac.be

Antithrombin (AT) inhibits thrombin and some other coagulation factors in a reaction that is dramatically accelerated by binding of a pentasaccharide sequence present in heparin/heparan-sulfate to a heparin-binding site on AT. Based on the involvement of R47 in the heparin/AT interaction and the frequent occurrence of R47 mutations in AT deficiency patients, targeted knock-in of the corresponding R48C substitution in AT in mice was performed to generate a murine model of spontaneous thrombosis. The mutation efficiently abolished the effect of heparin-like molecules on coagulation inhibition in vitro and in vivo. Mice homozygous for the mutation (ATm/m mice) developed spontaneous, life-threatening thrombosis, occurring as early as the day of birth. Only 60% of the ATm/m offspring reached weaning age, with further loss at different ages. Thrombotic events in adult homozygotes were most prominent in the heart, liver, and in ocular, placental, and penile vessels. In the neonate, spontaneous death invariably was associated with major thrombosis in the heart. This severe thrombotic phenotype underlines a critical function of the heparin-binding site of antithrombin and its interaction with heparin/heparan-sulfate moieties in health, reproduction, and survival, and represents an in vivo model for comparative analysis of heparin-derived and other antithrombotic molecules.


Key Words: coagulation • gene targeting • knock-in • heparin • antithrombin deficiency




This article has been cited by other articles:


Home page
BloodHome page
L. He, T. K. Giri, C. P. Vicente, and D. M. Tollefsen
Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II
Blood, April 15, 2008; 111(8): 4118 - 4125.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Rak, J. L. Yu, J. Luyendyk, and N. Mackman
Oncogenes, Trousseau Syndrome, and Cancer-Related Changes in the Coagulome of Mice and Humans.
Cancer Res., November 15, 2006; 66(22): 10643 - 10646.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
K. Yoshizawa, G. E. Kissling, J. A. Johnson, N. P. Clayton, N. D. Flagler, and A. Nyska
Chemical-Induced Atrial Thrombosis in NTP Rodent Studies
Toxicol Pathol, August 1, 2005; 33(5): 517 - 532.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. C. Edavettal, K. A. Lee, M. Negishi, R. J. Linhardt, J. Liu, and L. C. Pedersen
Crystal Structure and Mutational Analysis of Heparan Sulfate 3-O-Sulfotransferase Isoform 1
J. Biol. Chem., June 11, 2004; 279(24): 25789 - 25797.
[Abstract] [Full Text] [PDF]